Tracer library / [225Ac]Ac-PSMA-617
[225Ac]Ac-PSMA-617
Also written as PSMA-617; [Ac-225]Ac-PSMA-617; Ac-225-PSMA-617; Pluvicto
- Radionuclide
- Ac-225 t½ 14284.8 min
- Modality
- Therapy
- Production route
- —
- Stage
- Clinical research
- Syntheses indexed
- 5
What it is
- Compound class
- PSMA-617 – urea-based PSMA-targeting small molecule (DOTA-conjugated peptidomimetic)
- Target / mechanism
- Targets prostate-specific membrane antigen (PSMA) PMID 34385780
- Clinical application
- Targeted alpha therapy for metastatic castration-resistant prostate cancer PMID 32802197
- Theranostic pair
- [111In]In-PSMA-617
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | SPE | ~45% | ~95% | PSMA-617 Novartis | 42159963 2026 EJNMMI Radiopharm Chem For 225Ac labeling of PSMA-617, 225AcCl3 (0.92 MBq) was added to 0.2 M NH4OAc buffer (pH 5.2, 100 µL) in a 0.5 mL Eppendorf tube (LoBind), followed by the addition of PSMA-617 (1.0 nmol, 1.0 µL). - about 45% for [212Pb]Pb-PSMA-617 and [225Ac]Ac-PSMA-617 |
| Manual synthesis | — | — | — | — | PSMA-617 precursor ABX | 37797974 2023 J Nucl Med Radiolabeling was performed as previously described |
| Manual synthesis | — | SPE | 85%–87% | 97%–99% | PSMA-617 ABX | 34385780 2021 Indian J Nucl Med Ac-225 PSMA was prepared by adding the required amount (50–150 μg) of the peptidic precursor (PSMA-617) in 1 ml ascorbate buffer. - the radiopeptide was obtained with an adequate yield of 85%–87% |
| Manual synthesis n/a | — | — | >99% | 98 ± 1% | PSMA-617 | 34250876 2022 Curr Radiopharm PSMA-617 precursor was dissolved in 25 μL metal-free water (0.67 mg/mL) and combined with 500 μL 0.05M Tris buffer, pH 9. - high radiochemical yield (57 ± 3 μCi, >99%) |
| Manual synthesis n/a | — | SPE | — | — | PSMA-617 | 34053430 2022 Curr Radiopharm PSMA-617, DOTATATE were radiolabelled with 225Actinium in 0.1 M HCl in the presence of ascorbate buffer solution and passed through the C-18 light cartridge for purification |
Clinical literature
Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.
- Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant Prostate Cancer patients.2020 · Theranostics · Prospective
- Outcome and Renal Safety of PSMA-Targeted Radioligand Therapy in mCRPC Patients With Preexisting Impaired Renal Function.2025 · Clin Nucl Med · Retrospective
- Hematologic toxicity profile and efficacy of [225Ac]Ac-PSMA-617 α-radioligand therapy of patients with extensive skeletal metastases of castration-resistant prostate cancer.2022 · Eur J Nucl Med Mol Imaging · Retrospective
- Molecular imaging and biochemical response assessment after a single cycle of [225Ac]Ac-PSMA-617/[177Lu]Lu-PSMA-617 tandem therapy in mCRPC patients who have progressed on [177Lu]Lu-PSMA-617 monotherapy.2021 · Theranostics · Retrospective
- Tumor sink effect in PSMA-targeted theranostics: intra-patient evaluation of a cohort receiving 225Ac/177Lu-PSMA tandem radioligand therapy.2025 · Q J Nucl Med Mol Imaging · Clinical study
- 68 Ga-Prostate-Specific Membrane Antigen PET/CT in Imaging of Hemangiopericytoma.2023 · Clin Nucl Med · Clinical study
- mCRPC Patients Receiving 225Ac-PSMA-617 Therapy in the Post-Androgen Deprivation Therapy Setting: Response to Treatment and Survival Analysis.2022 · J Nucl Med · Clinical study
- Patients Resistant Against PSMA-Targeting α-Radiation Therapy Often Harbor Mutations in DNA Damage-Repair-Associated Genes.2020 · J Nucl Med · Clinical study
- Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving 225Ac-PSMA-617 Radioligand Therapy.2020 · J Nucl Med · Clinical study
- Correction to: 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study.2019 · Eur J Nucl Med Mol Imaging · Clinical study
Show all 13 clinical studies
- Treatment of brain metastases of castration-resistant prostate cancer with 225Ac-PSMA-617.2019 · Eur J Nucl Med Mol Imaging · Clinical study
- DNA damage in human whole blood caused by radiopharmaceuticals evaluated by the comet assay.2019 · Mutagenesis · Clinical study
- 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study.2019 · Eur J Nucl Med Mol Imaging · Clinical study
Precursor
Need this precursor?We can point you to suppliers for [225Ac]Ac-PSMA-617, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 35 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Diagnostic pair signal at discovery: YES - Ga-68, In-111. Compound class inferred from precursor name (not stated outright) -- PMID 42159963: 'PSMA-617 (1.0 nmol, 1.0 µL)'. Stage set/updated at stage 23 from PMID 38773983: 'At the forefront of clinical trials with 225Ac in PCa are PSMA-targeted TAT agents, notably [225Ac]Ac-PSMA-617, [225Ac]Ac-PSMA-I&T and [225Ac]Ac-J591.'. | Stage 30 (2026-09-18): Stage was 'investigational'; normalised to 'Clinical research', original wording kept here.